Investment

Genomics

AC Immune gets $4m Goradia grant to extend Parkinson's vaccine trial

The philanthropic grant extends Part 1 of the Phase 2 VacSYn trial of ACI-7104 by two years, with final Part 1 data due in
The philanthropic grant extends Part 1 of the Phase 2 VacSYn trial of ACI-7104 by two years, with final Part 1 data due in
The Biotech Times Editorial Team  · 
Genomics

Kyntra Bio roxadustat shows TI benefit in LR-MDS regardless of RS status

Post-hoc MATTERHORN data presented at EHA 2026 show roxadustat achieved transfusion independence in both RS-positive and RS-negative lower-risk MDS patients.
Post-hoc MATTERHORN data presented at EHA 2026 show roxadustat achieved transfusion independence in both RS-positive and RS-negative lower-risk MDS patients.
The Biotech Times Editorial Team  · 
Biotech

Linnaeus Therapeutics' LNS8801 selected for NIA lifespan testing

The GPER agonist joins the NIA's Interventions Testing Programme, complementing a separate $22m ARPA-H contract to evaluate healthspan preservation.
The GPER agonist joins the NIA's Interventions Testing Programme, complementing a separate $22m ARPA-H contract to evaluate healthspan preservation.
The Biotech Times Editorial Team  · 
Digital Health

Nyxoah raises $110m to accelerate Genio sleep apnoea launch in US

The Belgian medtech closed a $95m equity round and expects a $15m EIB loan tranche as it scales its FDA-approved Genio neurostimulator commercially.
The Belgian medtech closed a $95m equity round and expects a $15m EIB loan tranche as it scales its FDA-approved Genio neurostimulator commercially.
The Biotech Times Editorial Team  · 
Pharmaceuticals

Kymera Therapeutics doses first participant in IRAK4 degrader trial

KT-485's Phase 1 first-in-human start triggers a $20m milestone payment from Sanofi under their IRAK4 degrader collaboration.
KT-485's Phase 1 first-in-human start triggers a $20m milestone payment from Sanofi under their IRAK4 degrader collaboration.
The Biotech Times Editorial Team  · 

Standard BioTools and Treeline Biosciences agree all-stock merger

The combined company will operate as Treeline Biosciences, with over $900m in cash and three Phase 1 oncology programmes already under way.
The combined company will operate as Treeline Biosciences, with over $900m in cash and three Phase 1 oncology programmes already under way.
The Biotech Times Editorial Team  · 
Pharmaceuticals

Roche and Nurix strike $2.3bn BTK degrader deal for bexobrutideg

Roche will pay Nurix $700m upfront to co-develop and co-commercialise bexobrutideg across blood cancers, immunology and neurology.
Roche will pay Nurix $700m upfront to co-develop and co-commercialise bexobrutideg across blood cancers, immunology and neurology.
The Biotech Times Editorial Team  · 
Regulatory Science

PharmAla Biotech licenses ALA-002 U.S. rights to Jupiter Neurosciences

PharmAla will receive up to $100m in milestones and royalties for exclusive U.S. rights to its non-racemic MDMA candidate ALA-002.
PharmAla will receive up to $100m in milestones and royalties for exclusive U.S. rights to its non-racemic MDMA candidate ALA-002.
The Biotech Times Editorial Team  · 
Biotech

Nurix and Roche strike $2.3bn BTK degrader collaboration

Nurix Therapeutics receives $700m upfront from Roche to co-develop bexobrutideg across blood cancers, multiple sclerosis and urticaria.
Nurix Therapeutics receives $700m upfront from Roche to co-develop bexobrutideg across blood cancers, multiple sclerosis and urticaria.
The Biotech Times Editorial Team  · 
Digital Health

Health Catalyst divests Vitalware to Med-Metrix for $147m

Health Catalyst will sell its mid-revenue cycle unit to fund AI investment and fully repay a $160m term loan.
Health Catalyst will sell its mid-revenue cycle unit to fund AI investment and fully repay a $160m term loan.
The Biotech Times Editorial Team  · 
Biotech

GNI Group to acquire Ayumi Pharmaceutical in ¥44.8bn deal

The Tokyo-listed biopharmaceutical group is buying Blackstone's Japanese specialty pharma asset to build a cross-Pacific commercial platform.
The Tokyo-listed biopharmaceutical group is buying Blackstone's Japanese specialty pharma asset to build a cross-Pacific commercial platform.
The Biotech Times Editorial Team  · 
Regulatory Science

Agios licenses SYK inhibitor cevidoplenib from Oscotec in $1bn ITP deal

Agios will pay $25m upfront for global rights to cevidoplenib, a next-generation oral SYK inhibitor targeting immune thrombocytopenia, with Phase 3 planned for 2028.
Agios will pay $25m upfront for global rights to cevidoplenib, a next-generation oral SYK inhibitor targeting immune thrombocytopenia, with Phase 3 planned for 2028.
The Biotech Times Editorial Team  · 
Regulatory Science

Crossject closes €15m equity raise to advance ZEPIZURE EUA process

The Dijon-based emergency-medicines specialist issued new shares and warrants to fund regulatory steps for its needle-free seizure treatment and ramp production capacity.
The Dijon-based emergency-medicines specialist issued new shares and warrants to fund regulatory steps for its needle-free seizure treatment and ramp production capacity.
The Biotech Times Editorial Team  · 
Biotech

Ona Therapeutics raises $86.6m Series B to bring ADCs into clinic

The Barcelona biotech closed an oversubscribed round to advance its lead ADC, ONA-255, toward clinical proof of concept in breast cancer.
The Barcelona biotech closed an oversubscribed round to advance its lead ADC, ONA-255, toward clinical proof of concept in breast cancer.
The Biotech Times Editorial Team  · 
Regulatory Science

Attralus wins FDA orphan drug status for AL amyloidosis candidate AT-02

Zamubafusp alfa now holds four orphan designations globally as Attralus advances the pan-amyloid removal antibody through a Phase 2 trial.
Zamubafusp alfa now holds four orphan designations globally as Attralus advances the pan-amyloid removal antibody through a Phase 2 trial.
The Biotech Times Editorial Team  · 
Cell & Gene Therapy

Alpha Tau and Tolmar partner to commercialise Alpha DaRT in U.S.

Alpha Tau secures a $35M upfront package from Tolmar, plus up to $161.5M in milestones, for exclusive U.S. prostate cancer rights to its
Alpha Tau secures a $35M upfront package from Tolmar, plus up to $161.5M in milestones, for exclusive U.S. prostate cancer rights to its
The Biotech Times Editorial Team  · 
Bioinformatics
Diagnostics
Digital Health

Alzai Health files IPO prospectus on TSXV to raise up to C$4m

The Toronto-based AI Alzheimer's screening company plans to list on the TSX Venture Exchange in May, raising up to C$4 million at
The Toronto-based AI Alzheimer's screening company plans to list on the TSX Venture Exchange in May, raising up to C$4 million at
The Biotech Times Editorial Team  · 
Regulatory Science

Picard Medical prices $5m offering to clear debt and fund operations

The SynCardia parent raises $5m via shares and warrants at $0.30, using proceeds to repay senior secured notes and support working capital.
The SynCardia parent raises $5m via shares and warrants at $0.30, using proceeds to repay senior secured notes and support working capital.
The Biotech Times Editorial Team  · 
Regulatory Science

Orchestra BioMed receives $15m Ligand tranche, totalling $40m

Orchestra BioMed has drawn a scheduled $15m royalty-financing tranche from Ligand, bringing total Ligand capital to $40m to fund two pivotal cardiovascular device trials.
Orchestra BioMed has drawn a scheduled $15m royalty-financing tranche from Ligand, bringing total Ligand capital to $40m to fund two pivotal cardiovascular device trials.
The Biotech Times Editorial Team  · 
Subscribe to Investment